Tci Wealth Advisors, Inc. Biocryst Pharmaceuticals Inc Transaction History

Tci Wealth Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$7.94 - $11.84 $3,414 - $5,091	-430 Reduced 99.31%	3 $0
Q4 2022 Feb 06, 2023	SELL	$10.5 - $14.2 $31 - $42	-3 Reduced 0.69%	433 $4,000
Q3 2022 Nov 08, 2022	BUY	$10.79 - $14.81 $64 - $88	6 Added 1.4%	436 $5,000
Q2 2022 Jul 19, 2022	SELL	$7.89 - $17.88 $3,006 - $6,812	-381 Reduced 46.98%	430 $5,000
Q4 2021 Jan 24, 2022	BUY	$11.18 - $15.46 $1,978 - $2,736	177 Added 27.92%	811 $11,000
Q3 2021 Oct 29, 2021	BUY	$14.21 - $17.65 $6,920 - $8,595	487 Added 331.29%	634 $9,000
Q2 2021 Aug 02, 2021	SELL	$9.5 - $17.24 $484 - $879	-51 Reduced 25.76%	147 $2,000
Q1 2021 Apr 29, 2021	BUY	$7.37 - $13.61 $1,459 - $2,694	198 New	198 $2,000

257

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.57B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.